Targets › CALR
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. (UniProt, P27797)
Open in Phaseline: the race on CALR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Marina Kremyanskaya | Mutant-CALR peptide vaccine Mutant CALR peptide-based therapeutic vaccine | CALR | Phase 1 | Myelofibrosis | Mar 2027 |
| Johnson & Johnson (Janssen) | JNJ-88549968 CALR-targeting therapy for calreticulin-mutated myeloproliferative neoplasms | CALR | Phase 1 | Neoplasms | Jun 2027 |
Myelofibrosis (1) Neoplasms (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.